Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + doxorubicin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Combination chemotherapy of three small-molecule cytotoxic agents used investigationally and off‑protocol in oncology. Gemcitabine is a deoxycytidine analog that inhibits DNA synthesis through diphosphate-mediated ribonucleotide reductase inhibition and triphosphate incorporation causing chain termination. Doxorubicin is an anthracycline that intercalates DNA, inhibits topoisomerase II, and generates free radicals. Paclitaxel is a taxane that stabilizes microtubules and arrests cells in mitosis. This triplet has been studied primarily as an anthracycline–taxane backbone augmented by gemcitabine in metastatic breast cancer and cisplatin‑ineligible or renally impaired urothelial carcinoma, often on a biweekly schedule with growth factor support, showing activity with myelosuppression as a key toxicity.[1][7][3]
- Brand names
- GemzarAdriamycinTaxol
- Other names
- GATGTAgemcitabine-doxorubicin-paclitaxelgemcitabine + paclitaxel + doxorubicin
02
Targets
DNA (Deoxyribonucleic acid)TOP2A (DNA topoisomerase II)RRM1DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on gemcitabine + doxorubicin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + doxorubicin + paclitaxel.